Literature DB >> 1731324

Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit.

G J Tyrrell1, K Ramotar, B Toye, B Boyd, C A Lingwood, J L Brunton.   

Abstract

Verotoxin 1 (VT-1) and Shiga-like toxin II (SLT-II) bind to the glycosphingolipid (GSL), globotriaosylceramide (Gb3), whereas pig edema disease toxin (VTE) binds to globotetraosylceramide (Gb4) and to a lesser degree Gb3. Amino acids important in the GSL binding specificity of VT-1 and VTE have been identified by site-directed mutagenesis. One mutation, Asp-18----Asn, in VT-1 resulted in binding to Gb4 in addition to Gb3 in a manner similar to VTE. Several mutations in VTE resulted in the complete loss of GSL binding; however, one mutation resulted in a change in the GSL binding specificity of the VTE B subunit. The double mutation Gln-64----Glu and Lys-66----Gln (designated GT3) caused a selective loss of Gb4 binding, effectively changing the binding phenotype from VTE to VT-1. Both wild-type VTE and GT3 were purified to homogeneity and binding kinetics in vitro were determined with purified GSLs from human kidney. The cell cytotoxicity spectrum of the mutant toxin was also found to be altered in comparison with VTE. These changes were consistent with the GSL content of the target cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731324      PMCID: PMC48271          DOI: 10.1073/pnas.89.2.524

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.

Authors:  J E Samuel; L P Perera; S Ward; A D O'Brien; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

2.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

3.  Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.

Authors:  N A Strockbine; L R Marques; J W Newland; H W Smith; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

4.  Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis.

Authors:  M P Jackson; E A Wadolkowski; D L Weinstein; R K Holmes; A D O'Brien
Journal:  J Bacteriol       Date:  1990-02       Impact factor: 3.490

5.  Identification of the uvrA gene product.

Authors:  A Sancar; R P Wharton; S Seltzer; B M Kacinski; N D Clarke; W D Rupp
Journal:  J Mol Biol       Date:  1981-05-05       Impact factor: 5.469

6.  The human c-fps/fes gene product expressed ectopically in rat fibroblasts is nontransforming and has restrained protein-tyrosine kinase activity.

Authors:  P A Greer; K Meckling-Hansen; T Pawson
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

7.  Modification of the glycolipid-binding specificity of vero cytotoxin by polymyxin B and other cyclic amphipathic peptides.

Authors:  S Head; K Ramotar; C Lingwood
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli.

Authors:  N A Strockbine; L R Marques; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

9.  Experimental infection of infant rabbits with verotoxin-producing Escherichia coli.

Authors:  C H Pai; J K Kelly; G L Meyers
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  30 in total

1.  Induction of epithelial cell death including apoptosis by enteropathogenic Escherichia coli expressing bundle-forming pili.

Authors:  M Abul-Milh; Y Wu; B Lau; C A Lingwood; D Barnett Foster
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flowcytometric application.

Authors:  S Miyashita; Y Matsuura; D Miyamoto; Y Suzuki; Y Imai
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

3.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

4.  Neutral red assay for measurement of quantitative vero cell cytotoxicity.

Authors:  A Valdivieso-Garcia; R C Clarke; K Rahn; A Durette; D L Macleod; C L Gyles
Journal:  Appl Environ Microbiol       Date:  1993-06       Impact factor: 4.792

5.  Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30.

Authors:  D J Bast; J Sandhu; N Hozumi; B Barber; J Brunton
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Bimodal Response to Shiga Toxin 2 Subtypes Results from Relatively Weak Binding to the Target Cell.

Authors:  Patrick Cherubin; Dennis Fidler; Beatriz Quiñones; Ken Teter
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

7.  Enteropathogenic Escherichia coli virulence factor bundle-forming pilus has a binding specificity for phosphatidylethanolamine.

Authors:  C Khursigara; M Abul-Milh; B Lau; J A Girón; C A Lingwood; D E Barnett Foster
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

8.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.

Authors:  M Bitzan; M Klemt; R Steffens; D E Müller-Wiefel
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

9.  The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.

Authors:  S W Lindgren; J E Samuel; C K Schmitt; A D O'Brien
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

10.  Increased globotriaosylceramide on plasma membranes of synchronized familial dysautonomia cells. Verotoxin binding studies.

Authors:  J Pereira; B Boyd; J Newbigging; C Lingwood; P M Strasberg
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.